Everolimus-Eluting Platinum Chromium Coronary Stent System

play icon
play icon
Customized stent architecture for strength and flexibility.
Enhanced catheter design enables exceptional tracking, pushability and flexibility.
View product animation.
Dr. Antonio Colombo gives an overview of the Promus PREMIER Stent’s flexibility, conformability, visibility, and Everolimus drug/PVDF-HFP polymer combination.

PREMIER Architecture.
PREMIER Outcomes.

Features the only customized Platinum Chromium Stent architecture, the market-leading Everolimus drug and PVDF-HFP polymer combination and an enhanced catheter to provide Premier outcomes.

Key Resources


Product Details

Ordering Information

(mm) STENT LENGTH (mm)
  8 12 16 20
2.25 H7493952808220 H7493952812220 H7493952816220 H7493952820220
2.5 H7493952808250 H7493952812250 H7493952816250 H7493952820250
2.75 H7493952808270 H7493952812270 H7493952816270 H7493952820270
3 H7493952808300 H7493952812300 H7493952816300 H7493952820300
3.5 H7493952808350 H7493952812350 H7493952816350 H7493952820350
4 H7493952808400 H7493952812400 H7493952816400 H7493952820400
(mm) STENT LENGTH (mm)      
  24 28 32 38
2.25 H7493952824220 H7493952828220 H7493952832220 N/A
2.5 H7493952824250 H7493952828250 H7493952832250 H7493952838250
2.75 H7493952824270 H7493952828270 H7493952832270 H7493952838270
3 H7493952824300 H7493952828300 H7493952832300 H7493952838300
3.5 H7493952824350 H7493952828350 H7493952832350 H7493952838350
4 H7493952824400 H7493952828400 H7493952832400 H7493952838400
(mm) STENT LENGTH (mm)      
  8 12 16 20
2.25 H7493925208220 H7493925212220 H7493925216220 H7493925220220
2.5 H7493925208250 H7493925212250 H7493925216250 H7493925220250
2.75 H7493925208270 H7493925212270 H7493925216270 H7493925220270
3 H7493925208300 H7493925212300 H7493925216300 H7493925220300
3.5 H7493925208350 H7493925212350 H7493925216350 H7493925220350
4 H7493925208400 H7493925212400 H7493925216400 H7493925220400
(mm) STENT LENGTH (mm)      
  24 28 32 38
2.25 H7493925224220 H7493925228220 H7493925232220 N/A
2.5 H7493925224250 H7493925228250 H7493925232250 H7493925238250
2.75 H7493925224270 H7493925228270 H7493925232270 H7493925238270
3 H7493925224300 H7493925228300 H7493925232300 H7493925238300
3.5 H7493925224350 H7493925228350 H7493925232350 H7493925238350
4 H7493925224400 H7493925228400 H7493925232400 H7493925238400

Clinical Information

PLATINUM Workhorse Trial

Study Objective
Evaluate the safety and effectiveness of the Promus PtCr EES Stent System1 for the treatment of patients with up to 2 de novo lesions ≤ 24 mm in length; ≥ 2.50 mm to ≤ 4.25 mm in diameter compared to the Xience CoCr EES

Study Design
Prospective, Randomized, Controlled, Non-inferiority, Multicenter

4-Year Clinical Results

Numerically Lower Event Rates1

Complex Patients

Boston Scientific has received approval to update the indications section of the Directions for Use to include the treatment of patients presenting with coronary artery ostial lesions, unprotected left main coronary artery lesions, coronary artery total occlusion lesions, and in-stent restenosis in coronary artery lesions.
Added recommendations include: For treatment of occluded vessels, contrast visualization of the distal vessel to confirm position of guidewire within the lumen is recommended. For in stent restenosis, where details of the original stent are known, the expanded inner diameter of the new stent should not exceed the dilation limits of the original stent. Where details of the original stent are not known, the expanded inner diameter of the new stent should not exceed the reference vessel diameter.
* The updated Directions for Use will also include an update on the current “Pre-and Post-Procedure Antiplatelet Regimen”: 
In selected higher risk patients where the physician determines that the risks outweigh the benefits of continued DAPT, it may be reasonable to interrupt or discontinue therapy after 1 month based on low stent thrombosis rates and no observed increased risk for stent thrombosis as shown in the current literature.  Patients who require premature discontinuation of antiplatelet therapy should be monitored closely and have their antiplatelet therapy restarted as soon as possible per the discretion of their treating physicians.

Tools and Resources